Efficacy and safety of pegylated interferon alfa-2a or alfa-2b plus ribavirin for the treatment of chronic hepatitis C in children and adolescents: a systematic review and …

E Druyts, K Thorlund, P Wu, S Kanters… - Clinical infectious …, 2013 - academic.oup.com
Background. A systematic review and meta-analysis were conducted to examine the efficacy
and safety of pegylated interferon (peg-IFN) alfa-2a and peg-IFN alfa-2b plus ribavirin (RBV) …

Analysis of hepatitis C virus decline during treatment with the protease inhibitor danoprevir using a multiscale model

L Rong, J Guedj, H Dahari, DJ Coffield Jr… - PLoS computational …, 2013 - journals.plos.org
The current paradigm for studying hepatitis C virus (HCV) dynamics in patients utilizes a
standard viral dynamic model that keeps track of uninfected (target) cells, infected cells, and …

What the infectious disease physician needs to know about pegylated interferon and ribavirin

N Gara, MG Ghany - Clinical infectious diseases, 2013 - academic.oup.com
The treatment of chronic hepatitis C is rapidly evolving from triple therapy to regimens that
do not require interferon or even ribavirin. However, pegylated interferon and ribavirin will …

[HTML][HTML] The effect of peginterferon alpha-2a vs. peginterferon alpha-2b in treatment of naive chronic HCV genotype-4 patients: a single centre Egyptian study

M El Raziky, WF Fathalah, WA El-Akel, A Salama… - Hepatitis …, 2013 - ncbi.nlm.nih.gov
Background Egypt has one of the highest (16-8%) prevalence rates of HCV infection in the
world. Approximately 90% of Egyptian HCV isolates belong to a single subtype (4a), which …

Modelling heterogeneity variances in multiple treatment comparison meta-analysis–are informative priors the better solution?

K Thorlund, L Thabane, EJ Mills - BMC medical research methodology, 2013 - Springer
Background Multiple treatment comparison (MTC) meta-analyses are commonly modeled in
a Bayesian framework, and weakly informative priors are typically preferred to mirror familiar …

Psychological, lifestyle and social predictors of hepatitis C treatment response: a systematic review

VA Sublette, MW Douglas, K McCaffery… - Liver …, 2013 - Wiley Online Library
Background To increase cure rates for Hepatitis C, barriers to treatment adherence and
completion must be identified and overcome. Aims This study systematically reviewed …

Pegylated interferon-α2a and ribavirin versus pegylated interferon-α2b and ribavirin in chronic hepatitis C: a meta-analysis

N Flori, N Funakoshi, Y Duny, JC Valats, M Bismuth… - Drugs, 2013 - Springer
Introduction Results of trials and meta-analyses comparing pegylated interferon (PEG-IFN)-
α2a and PEG-IFN-α2b for the treatment of chronic hepatitis C are conflicting. Objective Our …

Meta-analysis: mortality and serious adverse events of peginterferon plus ribavirin therapy for chronic hepatitis C

T Minami, T Kishikawa, M Sato, R Tateishi… - Journal of …, 2013 - Springer
Abstract Background Pegylated interferon (PEG-IFN) plus ribavirin (RBV) therapy is the
current standard of care for patients with chronic hepatitis C. Determining precisely the risk …

Multicenter comparison of PEG-IFN α2a or α2b plus ribavirin for treatment-naïve HCV patient in Korean population

YJ Jin, JW Lee, JI Lee, SH Park, CK Park, YS Kim… - BMC …, 2013 - Springer
Abstract Background Two recent Italian studies suggested that Pegylated-interferon (PEG-
IFN) alfa-2a achieves a higher sustained virological response (SVR) rate than PEG-IFN alfa …

[HTML][HTML] Pegylated interferon alfa and ribavirin for children with chronic hepatitis C

I Rosen, M Kori, OE Adiv, B Yerushalmi… - World journal of …, 2013 - ncbi.nlm.nih.gov
AIM: To study current treatment options for pediatric hepatitis C infection and their
associated success rates. METHODS: We retrospectively reviewed charts of thirty children …